Company Description
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers.
It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics.
The company’s offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs.
The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally.
The company was incorporated in 2018 and is based in Fremont, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Apr 17, 2026 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 222 |
| CEO | Yuling Luo |
Contact Details
Address: 47071 Bayside Parkway Fremont, California 94538 United States | |
| Phone | (510) 626-9888 |
| Website | alamarbio.com |
Stock Details
| Ticker Symbol | ALMR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0002104204 |
| CUSIP Number | 010911105 |
| ISIN Number | US0109111056 |
| Employer ID | 36-4899036 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Yuling Luo, Ph.D. | Founder, Chief Executive Officer and Chairman |
| Timothy “Tod” White | President |
| Justin McAnear | Chief Financial Officer |
| Shiping “Steve” Chen, Ph.D. | Founder, Chief Operating Officer and Director |
| Rebecca Chambers | Director |
| Nicholas Naclerio, Ph.D. | Director |
| Ian W. Ratcliffe | Director |
| Frank R. Witney, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2026 | SCHEDULE 13D | Filing |
| Apr 23, 2026 | SCHEDULE 13D | Filing |
| Apr 20, 2026 | EFFECT | Notice of Effectiveness |
| Apr 20, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 20, 2026 | 8-K | Current Report |
| Apr 20, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 17, 2026 | 424B4 | Prospectus |
| Apr 16, 2026 | EFFECT | Notice of Effectiveness |
| Apr 16, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Apr 16, 2026 | CERT | Certification by an exchange approving securities for listing |